HUTCHMED’s Post

The latest hematology updates in one place! 🌎🔴 This was the summary of the MENA Hematology conference, watch it now 🚨⏬ Proudly Managed By #EventTroop

The latest hematology updates in one place! 🌎🔴 This was the summary of the MENA Hematology conference, watch it now 🚨⏬ Proudly Managed By #EventTroop

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Today we presented real-world evidence evaluating a CD-19-directed antibody for relapsed or refractory DLBCL at the American Society of Hematology Annual Meeting. Check out the abstract to learn more. #ASH23 https://bit.ly/47KZjkM

Do carve out time in your busy schedule to meet Jennell and learn about RBC health biomarkers.

#Sanofi_Greater_Gulf Sanofi Hematology Summit gathers international and local experts, exchanging insights on #aTTP and #multiple_myeloma management, and laying the groundwork for future innovations in patient care

Excited to share preliminary data from the Century Therapeutics, Inc ELiPSE-1 trial and a case study of a patient who maintained a CR while receiving four 28 day cycles of CNTY-101 at the lowest dose level. CNTY-101 is engineered with six precision edits, including ALLO-EVASION technology to enable repeat dosing. Importantly, this patient's first two cycles included lymphodepletion while the next two did not. No pre-existing or induced anti-drug antibodies were detected and each infusion demonstrated comparable kinetics. These early results are encouraging for both oncology and non-oncology indications, where the side effect profile of lymphodepletion may be prohibitive. #ipsc #celltherapy #geneediting #oncology #autoimmune

Nucleic acid therapeutics are currently the third major drug class after small molecule and antibodies, and are expected to keep gaining momentum in the near future. The current article provides an elegant review of the challenging history of the field, milestones and anticipated innovation. With the promise of reaching organs previously inaccessible to the field, different nucleic acid therapeutic modalities are currently investigated in 80 clinical trials- mainly 20 for liver targets, 10 for CNS targets, 10 for oncological targets, and others in the muscle, skin, lung, eye, or placenta. Link: https://lnkd.in/e7idfQXZ #RNAi #siRNA #ASO #oligonucleotides #CRISPR #aptamers

The Hematology Round Up from #ASCO24 (Multiple Myeloma) Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). https://lnkd.in/d2dRh6Hp Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). https://lnkd.in/dSjVvk7X Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Thank you for your attention and enjoy ASCO Disclosure: This Hematology Round Up was supported by Sanofi https://lnkd.in/d9ic5mpy